The probability of success to move an investigational drug from Phase I to market is at less than 10% across all therapy areas. For those that do progress to Phase II and III trials, more than half fail due to lack of efficacy.

With 20,000+ genes and proteins, and hundreds of millions of compounds known in nature, improving success rates through manual research methods is a daunting task. Biologists simply do not have the time or funds needed to make confident, informed decisions. Dimensions Life Sciences and Chemistry ( Dimensions L&C) can change this. With one of the world’s largest sets of scientific full-text content and AI search functionality, biologists can quickly identify detailed, accurate information on disease mechanisms and potential drug targets.

Improving efficacy failure rates in drug trials

In past publications, AstraZeneca and Pfizer both highlighted the direct correlation between clinical success and understanding of target and disease biology. AstraZeneca noted 40% of its efficacy failures had no target-disease linkage established, whilst 82% of projects with efficacy biomarkers succeeded. Similarly, Pfizer found that 43% of their efficacy failures did not have a sufficiently tested mechanism of action.

Dimensions L&C improves target assessment in biomedical research, avoiding later stage failures in clinical trials by establishing strong target-disease linkage. Semantic analysis and ontology-based search tools offer research biologists powerful, up-to-date data. The search tools complement existing methods, offering greater insight into pathways, genes and proteins as well as pathophysiological processes. 

Watch our video to see how you can quickly understand disease mechanisms in action.

Using Semantic Co-occurrence Search to build accurate hypotheses on drug targets

Dimensions L&C offers access to over 120 million scientific publications, as well as millions of patents, grants and clinical trial documents. By applying Semantic Search, the system generates insights about a disease of interest, the molecular mechanisms that cause it and its related genes and proteins, by correlating a disease with 40 million concepts.

Data can also be distilled through the use of Co-occurrence Search. Dimensions L&C analyses hundreds of millions of documents to identify when two terms are mentioned in close textual proximity. Delivered within seconds, the results enable scientists to correlate findings into mechanisms of action or pathologies. 

Simple tabs allow further exploration, for example into pathways or genes and proteins. There are options to sort the findings based on frequencies of co-occurrences, occurrences of terms/ concepts in patent claims or clinical trials to provide more specific results. At any point scientists can explore the concepts found by clicking on source links. 

Bringing more drugs to market

The Dimensions L&C database continues to evolve and grow as more published data is added. Research and development biologists can make fast, confident, data-driven decisions about disease mechanisms, as well as drug targets and compounds, safe in the knowledge they have researched all available information. With improved insight at this early stage, pharmaceuticals can potentially avoid later stage failures in clinical trials and ultimately bring new and innovative treatment solutions to market faster than ever before.

To learn more about how Dimensions L&C could reduce research discovery time, minimize efficacy failure and help bring new drugs to market, request a consultation today.